Which specific bacteria does tigecycline excel against?

Tigecycline shows the strongest activity against gram-positive bacteria that resist other tetracycline antibiotics, particularly methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

How does tigecycline differ from older tetracyclines against resistant gram-positives?
Tigecycline binds the 30S ribosomal subunit in a way that evades the Tet(M) and Tet(O) ribosomal protection proteins that neutralize tetracycline, minocycline, and doxycycline. This single structural change restores activity against isolates that carry those genes.

Which gram-negative organisms does tigecycline reliably cover?
It retains activity against many multidrug-resistant Enterobacterales, including extended-spectrum beta-lactamase producers and some carbapenem-resistant Klebsiella and E. coli, but it lacks reliable effect against Pseudomonas and Proteus.

What about anaerobic coverage?
Tigecycline is active against most Bacteroides and Clostridium species, giving it a role in complicated intra-abdominal infections where anaerobes predominate.

When do clinicians turn to tigecycline instead of linezolid or daptomycin?
Its broad gram-positive and gram-negative spectrum lets it serve as monotherapy in polymicrobial skin, soft-tissue, and intra-abdominal infections, avoiding the need to combine linezolid with a gram-negative agent.

Why do some hospitals restrict tigecycline use?
Resistance can emerge through upregulation of efflux pumps, and FDA warnings note higher all-cause mortality in certain severe infections compared with other agents; these concerns limit its first-line status.

When does the tigecycline composition-of-matter patent expire?
The primary U.S. patent covering tigecycline expired in 2015, but method-of-use and formulation patents extend protection for specific indications through at least 2025. Generic versions are already marketed in several countries.